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A B S T R A C T
In 80 adult patients with community acquired pneumonia (CAP) conventional microbiological methods, polymerase
chain reaction (PCR) and serum C-reactive protein (CRP) levels were performed and the appropriateness of the empirical
antimicrobial treatment was evaluated according to bacterial pathogen detected. The aetiology was determined in 42
(52.5%) patients, with Streptococcus pneumoniae as the most common pathogen. PCR applied to bronchoalveolar lavage
(BAL) provided 2 and PCR on sputum samples 1 additional aetiological diagnosis of CAP. The mean CRP values in the
S. pneumoniae group were not significantly higher than in the group with other aetiological diagnoses (166.89 mg/L
vs.160.11 mg/L, p=0.457). In 23.8% (10/42) of patients with determined aetiology, the empirical antimicrobial treatment
was inappropriate. PCR tests need further investigation, particularly those for the atypical pathogens, as they are pre-
dominant in inappropriately treated patients. Our results do not support the use of CRP as a rapid test to guide the
antimicrobial treatment in patients with CAP.
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Introduction
Community acquired pneumonia (CAP) is a common
disease and a frequent cause of morbidity and mortality
worldwide. In most studies, Streptococcus pneumoniae
remains the most frequent bacterial cause of CAP in
adult patients. The incidence of other bacterial patho-
gens varies widely and depends on the geographical area,
factors related to the population being studied and mi-
crobiological tests used. In 50–70% of patients with CAP
the aetiologic agent is not identified, even in carefully
conducted prospective studies of pneumonia aetiology1–6.
Fast and sensitive tests are therefore needed to guide
antimicrobial treatment in patients with CAP.
Due to the imperfection of traditional microbiological
methods, polymerase chain reaction (PCR) is increas-
ingly being used in order to rapidly determine the aetio-
logical diagnosis of CAP7–11. Also, usefulness of the se-
rum C-reactive protein (CRP) levels as an early indicator
of aetiology has been previously analyzed but data were
discordant12–14. During recent years, its usefulness in di-
agnosis of CAP is considered again15–19.
Ideally, antimicrobial treatment should be directed
against the pathogen that is causing the pneumonia.
However, as the aetiology is often not known at presenta-
tion, patients are initially receiving empirical antimicro-
bial treatment. Ewig et al. showed that without microbi-
ological diagnostic results, 21% of cases would have been
treated with an inappropriate empirical regimen. How-
ever, their findings were based solely on blood culture,
bronchoscopy and serology, and molecular methods were
not used20. In a recent study by van der Eerden et al. ini-
tial antimicrobial treatment guided by the clinical and
epidemiological presentation was at least effective as
treatment guided by the results of rapid microbiological
investigation. In that study molecular methods were not
used either21.
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Therefore, the objective of this study was to deter-
mine the diagnostic yield of microbiological tests, both
conventional and molecular, in patients with bacterial
CAP. CRP serum levels as an early marker of the aetiol-
ogy of CAP was also evaluated. Finally, the value of con-
ventional and molecular microbiological tests in direct-
ing antimicrobial treatment was determined by evalua-
tion of the empirical antimicrobial treatment according
to the bacterial pathogen detected.
Patients and Methods
Patients
Between February 2007 and January 2008, we pro-
spectively studied 80 patients (aged >18 yr) admitted for
CAP to the Department of Pulmonology, Zagreb Univer-
sity Hospital Center, Zagreb, Croatia.
The diagnostic criteria for CAP included a new infil-
trate on chest radiograph or auscultatory findings con-
sistent with pneumonia with symptoms of acute lower
respiratory tract infection including several (at least 2) of
the following: fever or hypothermia, rigors, sweats, new
cough with or without sputum production or change in
color of respiratory secretions in a patient with chronic
cough, chest discomfort, or the onset of dyspnea. Pa-
tients hospitalized or residing in a long-term-care facility
within the previous 14 days were excluded22.
The assessment of the severity of CAP was performed
using the Pneumonia Severity Index (PSI). Patients me-
eting a PSI score of IV and V were considered as having a
severe pneumonia22,23.
Empirical antimicrobial regimens were classified as
beta-lactam monotherapy, beta-lactam plus macrolide,
macrolide monotherapy, quinolone monotherapy and other
regimens.
The study was approved by the ethics committee of
School of Medicine, University of Zagreb (date of issue 6
February 2007, registration number 04-76/2007-32). The
patients gave their informed consent to participate in
this study.
Microbiological and laboratory investigations
Clinical specimens obtained in the study included
sputum samples for bacterial culture and PCR, urine
samples for bacterial antigen detection and serum sam-
ples for PCR and serological testing. Serum samples for
serological testing were drawn during the acute stage of
illness and 3–4 weeks later. Serum samples were also
used for determining CRP levels by an automated ana-
lyzer (Boehringer Mannheim; Mannheim, Germany) wi-
thin 24 hours of admission. Blood samples for bacterial
culture and bronchoalveolar lavage (BAL) samples for
bacterial culture and PCR were obtained according to the
clinical judgment of the physician in charge.
Standard methods were used for bacterial culture.
Sputum data were evaluated only in samples with >25
polymorphonuclear leucocytes and <10 epithelial cells
per low-power microscopy field.
Urine samples were tested for pneumococcal antigen
(NOW Streptococcus pneumoniae test; Binax Inc., Maine,
US) and, in case of severe pneumonia, for Legionella
pneumophila serogroup 1 antigen (NOW Legionella Uri-
nary Antigen Test; Binax Inc., Maine, US).
Chlamydophila pneumophila and L. pneumophila se-
rogroup 1–7 antibodies IgG and IgM, as well as Myco-
plasma pneumoniae IgA, IgM and IgG antibodies in
paired sera from the acute and convalescent phase were
determined using commercial enzyme immunoassay kits
(NovagnostTM, Dade Behring Marburg GmbH, Marburg,
Germany; SERION ELISA, Institut Virion/Serion GmbH,
Würzburg, Germany).
DNA for PCR reactions was extracted using the High
Pure PCR Template Preparation Kit (Roche Diagnostics,
Mannheim, Germany).
PCR for S. pneumoniae and C. pneumoniae was per-
formed as previously described7,10. For M. pneumoniae
and Legionella species commercial PCR kits were used
(Venor®Mp and Onar®Ls, Minerva Biolabs, Berlin, Ger-
many). PCR for S. pneumoniae was performed on serum
and BAL samples with the same PCR method. The only
difference was that BAL samples (because of their vis-
cosity) were treated with mucolytic agent 6% N-acetyl-L-
-cysteine prior to DNA isolation. PCR for for C. pneumo-
niae, M. pneumoniae and Legionella species was perfor-
med on sputum and BAL samples.
Empirical antimicrobial treatment was that one pre-
scribed within the first 24 hours of admission.
Criteria for aetiological diagnosis
Categorisation of positive microbiological test results
into definite, probable, and possible bacterial aetiologies
of community-acquired pneumonia was done as previ-
ously described24,25.
Criteria for definite aetiology were the following: 1)
blood cultures or pleural fluid cultures yielding a bacte-
rial pathogen; or 2) positive urinary L. pneumophila
serogroup 1 antigen; or 3) detection of Legionella species
by PCR from sputum or BAL sample; or 4) seroconver-
sion or antibody titre increase (according to manufac-
turer’s interpretation) of M. pneumoniae IgG, C. pneu-
moniae IgG, or L. pneumophila serogroup 1–7 IgG.
Criteria for probable aetiology were the following: 1)
positive urinary pneumococcal antigen; or 2) positive
sputum culture when a predominant microorganism was
isolated from purulent sample and the finding of Gram
stain was compatible; or 3) positive BAL culture when
the organism was isolated in numbers 104 colony-form-
ing units/ml; or 4) detection of M. pneumoniae or C.
pneumoniae by PCR from sputum or BAL sample; or 5)
positive IgA or IgM antibodies for M. pneumoniae, or
positive IgM antibodies for C. pneumoniae.
Criterion for possible aetiology was detection of S.
pneumoniae by PCR from serum or BAL sample.
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Statistical analysis
Means of serum CRP levels among different aetio-
logical groups were compared by using two-tailed unpaired
t-tests. Values of p<0.05 were considered significant.
Results
Patients’ characteristics
The demographic and clinical characteristics of the 80
patients with CAP included in the study are described in
Table 1. Sixty-one patients (76.3%) had at least one un-
derlying disease. In 24 (30.0%) patients antimicrobial
treatment was taken prior to hospital admission for
pneumonia. According to the PSI score, 23 (28.8%) pa-
tients were in class I, 9 (11.3%) in class II, 16 (20.0%) in
class III, and 32 (40.0%) in classes IV and V combined.
Aetiology of pneumonia and yield of different
microbiological methods
The microbial aetiology of CAP was established in 42
(52.5%) patients with a total of 49 bacterial pathogens
detected. A single pathogen was detected in 35 (43.8%)
and 2 pathogens in 7 (8.8%) patients. Bacterial patho-
gens according to criteria for aetiological diagnosis are
described in Table 2. Of these, 2 fulfilled the criteria for a
definite, 45 for probable and 2 for possible aetiology. S.
pneumoniae was the most common pathogen and was
identified in 25 (31.3%) patients followed byM. pneumo-
niae in 7 (8.8%) and Haemophilus influenzae in 5 (6.3%)
patients. S. pneumoniae withH. influenzae was the most
common combination and was detected in 3 patients.
Diagnostic yield of various microbiological methods is
described in Table 3. Urine samples for the pneumo-
coccal urinary antigen detection was obtained from 76
(95.0%) patients. The test result was positive in 16 (21.1%)
patients. In 14 (18.4%) of the 76 patients tested, the
pneumococcal urinary antigen test was the only test pos-
itive and provided an additional diagnosis that other di-
agnostic tests did not provide. L. pneumophila serogroup
1 antigen detection was performed in urine samples from
32 patients and 2 (6.3%) were positive.
Blood cultures were obtained in 11 (13.8%) patients
and they were all negative.
Sputum and BAL samples were obtained from 64
(80.0%) and 19 (23.8%) patients, respectively. Sputum
samples were adequate for culture in 36 (56.3%) pa-
tients. Bacterial pathogens were isolated in 17 (26.6%) of
these patients including 8 cases of S. pneumoniae, 3
cases of H. influenzae, 4 cases of Pseudomonas aeru-
ginosa, and 2 cases of K. pneumoniae. BAL culture was
positive in 5 (26.3%) patients including 1 case of S.
pneumoniae, 1 case of H. influenzae, 1 case of P. aeru-
ginosa, and 2 cases of K. pneumoniae.
S. pneumoniae PCR was positive in 15.8% (3/19) BAL
samples. All patients who underwent fibreoptic bron-
choscopy (FOB) had taken antimicrobial treatment prior
to bronchoscopic examination. Serum samples for S.
pneumoniae PCR was obtained from 79 patients and all
were PCR-negative. M. pneumoniae PCR was positive in
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TABLE 1
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF 80
PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
Characteristics
Number (%)
of patients*
Age (X±SD) 62.6±15.5
Male gender 52 (65.0)
Smokers 23 (28.8)
Underlying disease
Cardiovascular disease
Chronic obstructive pulmonary disease
Diabetes mellitus
Neoplasia
Cerebrovascular disease
Asthma
Chronic renal failure
27 (33.8)
21 (26.3)
8 (10.0)
7 (8.8)
5 (6.3)
3 (3.8)
2 (2.5)
Distribution according to PSI score
PSI I-III
PSI IV-V
48 (60.0)
32 (40.0)
*Dara are presented as number of subjects (%) unless otherwise
indicated, PSI – pneumonia severity index
TABLE 2
BACTERIAL PATHOGENS IN 80 PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA ACCORDING TO CRITERIA FOR
AETIOLOGICAL DIAGNOSIS
Bacterial pathogen
Definite diagnosis
N
Probable diagnosis
N
Possible diagnosis
N
Streptococcus pneumoniae
Mycoplasma pneumoniae
Haemophilus influenzae
Chlamydophila pneumoniae
Pseudomonas aeruginosa
Legionella species
Klebsiella pneumoniae
0
0
0
0
0
2
0
23
7
5
4
4
0
2
2
0
0
0
0
0
0
*Numbers include 7 patients with dual bacterial pathogens (S. pneumoniae with H. influenzae, 3 patients; S. pneumoniae with K.
pneumoniae, 1 patient; S. pneumoniae with M. pneumoniae, 1 patient; P. aeruginosa with M. pneumoniae, 2 patients)
1.6% (1/64) of sputum samples and BAL samples were
negative. PCR tests for C. pneumoniae and Legionella
species were negative in sputum and BAL samples.
A total of 6 cases of M. pneumoniae and 4 cases of C.
pneumoniae pneumonia were identified by serology. IgM
antibodies for L. pneumophila serogroup 1–7 in all serum
samples were negative. IgG antibodies were positive in 2
serum samples, but there was no 4-fold increase in anti-
body levels in convalescent phase serum.
CRP values compared with causative pathogens
Out of 80 patients with CAP, 51 had a CRP measure-
ment within the first 24 hours of admission. Mean CRP
levels according to the respective bacterial pathogens are
shown in Table 4. When grouping the patients in those
with S. pneumoniae (N=30) and those with all other
pathogens detected (N=11), the mean CRP values in the
S. pneumoniae group were not significantly higher than
in the group with other aetiological diagnoses (166.89
mg/L vs. 160.11 mg/L, p=0.457). Also, the mean CRP val-
ues in patients with S. pneumoniae were not signifi-
cantly higher than in patients with CAP of unknown ae-
tiology (166.89 mg/L vs. 148.72 mg/L, p=0.519).
Evaluation of empirical antimicrobial treatment
The relation between the empirically selected antimi-
crobial agents for 80 patients and the respective bacterial
pathogens is shown in Table 5. In 10 (23.8%) out of 42 pa-
tients with determined aetiology, the initially selected
antimicrobial agents were retrospectively considered in-
appropriate. Antimicrobials were inappropriately used in
4 patients with C. pneumoniae, 2 patients with P. aerugi-
nosa, 2 patients with P. aeruginosa plus M. pneumoniae,
1 patient with M. pneumoniae, and 1 patient with L.
pneumophila serogroup 1 infection. In 8 (80%) out of 10
inappropriately treated patients, established aetiological
agents were atypical pathogensM. pneumoniae, C. pneu-
moniae and L. pneumophila serogroup 1.
Discussion
In most cases, the initial approach in patients with
CAP involves empirical antimicrobial treatment. The
main problem for clinicians is to estimate the likely bac-
terial pathogen and to select the most appropriate anti-
microbial agents. Fast microbiological methods and early
markers for guiding the clinician in the initial selection
of antimicrobial treatment are therefore needed.
In this study PCR was used simultaneously with con-
ventional microbiological methods to determine the bac-
terial pathogens in patients with CAP.
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TABLE 3
DIAGNOSTIC YIELD OF MICROBIOLOGICAL METHODS IN 80 PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
Microbiological method Number of positive/tested (%)
Streptococus pneumoniae antigen detection in urine sample
Legionella pneumophila serogroup 1 antigen detection in urine sample
Blood cultures
Sputum culture
BAL culture
Streptococcus pneumoniae PCR in serum
Streptococcus pneumoniae PCR in BAL
Mycoplasma pneumoniae PCR in sputum
Mycoplasma pneumoniae PCR in BAL
Chlamydophila pneumoniae PCR in sputum
Chlamydophila pneumoniae PCR in BAL
Legionella species PCR in sputum
Legionella species PCR in BAL
Serology*
16/76 (21.1)
2/32 (6.3)
0/11
17/64 (26.6)
5/19 (26.3)
0/70
3/19 (15.8)
1/64 (1.6)
0/19
0/64
0/19
0/64
0/19
10/79 (12.7)
*Including serology for M. pneumoniae, C. pneumoniae and Legionella pneumophila serogroup 1-7
BAL – bronchoalveolar lavage, PCR – polymerase chain reaction
TABLE 4
SERUM CRP VALUES ACCORDING TO CAUSATIVE PATHOGEN
IN 51 PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
Causative pathogens Patients
N
CRP X
mg/L
Streptococcus pneumoniae
Legionella pneumophila*
Mycoplasma pneumoniae*
Chlamydophila pneumoniae*
Other
Patients with >1 pathogen
identified*
CAP of unkonwn aetiology
11
2
3
4
2
3
26
177.11
380.4
106.97
185.63
118.4
234.27
148.72
Total 51
*Not included in statistycal analyses due to the small number of
cases
CRP – C-reactive protein
The most useful method for identifying S. pneumo-
niae in our study was the pneumococcal urinary antigen,
as was the case in some previous studies25. There is no
reason to doubt in a cross-reactions with other micro-or-
ganisms and a reliability of positive pneumococcal uri-
nary antigen in patients in which this was the only test
positive for S. pneumoniae. Beside manufacturer’s per-
formance data which claims the possibility of false-posi-
tive results only in healthy children with nasopharyngeal
carriage of S. pneumoniae and in the 48 hours following
pneumococcal vaccination, there is also a plenty of scien-
tific data supporting a high specifity of this test. In our
study only the adult patients were included, and none of
the patients received pneumococcal vaccine 48 hours be-
fore testing. In the study by Genne et al., 67 adults with
CAP were compared with 81 patients with suspected uri-
nary tract infection to determine sensitivity and specific-
ity of pneumococal urinary antigen test. An aetiology
could be found for 22 (33%) using conventional methods
and increased to 33 patients (49%) with the addition of
the urinary antigen test. Nine out of 14 patients diag-
nosed with S. pneumoniae as the aetiologic agent for
their CAP had detectable urinary antigen levels (sensi-
tivity 64%; 1/81 positive control urine samples, specific-
ity 99%). Pneumococcal infection was diagnosed by pneu-
mococcal urinary antigen in 24% without an aetiologic
identification by conventional methods26. High specific-
ity of pneumococcal urinary antigen test was also deter-
mined in a study by Diederen et al27. Our results may be
somewhat diminished by the fact that a positive result of
pneumococcal urinary antigen test may persist in pa-
tients with chronic obstructive pulmonary disease or re-
cent pneumococcal infection28. However, S. pneumoniae
remains the most frequent bacterial cause of CAP in
most studies including adult patients1–6. Therefore, we
agree with authors who claim that it might be justified to
use pneumoccocal urinary antigen test as a basic test for
diagnosis of pneumococcal pneumonia25.
Blood cultures were obtained in 13.8% patients. In
our study we considered it unnecessary to perform the
blood cultures in every patient. Several studies have pro-
vided evidence that their sensitivity in CAP is low (par-
ticularly for patients with non-severe CAP, no co-morbid
disease and for those who have received antimicrobial
treatment before admission), and, when management
decisions are analyzed, the impact of positive blood cul-
tures is minor29–32. Therefore, in our study we left the de-
cision for obtaining the blood cultures to the clinical
judgment of the physician in charge. The explanation for
all negative blood cultures (N=11) in our study could be
prior antimicrobial treatment in 1 patient and pneumo-
nia severity of PSI class I-II in 6 patients. The PCR tests
for S. pneumoniae applied to serum samples were not
useful as a diagnostic test for pneumococcal pneumonia.
Because of inhibitors that could be present in serum
samples, in our study we did: 1. dilution of serum sam-
ples by pooling; in this way the amount of inhibitors pos-
sibly present in serum samples was decreased; and 2. re-
peating of PCR reaction after spiking of PCR-negative
serum samples prior to amplification with pneumococcal
DNA previously isolated from bacterial suspension of S.
pneumoniae; in this way the presence of PCR-inhibitors
and false-negative PCR results were excluded. This pro-
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TABLE 5
DESCRIPTION OF EMPIRICAL ANTIMICROBIAL TREATMENT ACCORDING TO BACTERIAL PATHOGENS IN 80 PATIENTS WITH CAP
Causative pathogen
Antimicrobial agents used
Number of
patients
Beta-lactam
monotherapy
Beta-lactam
plus macrolide
Quinolone
monotherapy
Macrolide
monotherapy
Other regimen
Streptococcus pneumoniae 20 10 5 3 1 1
Streptococcus pneumoniae +
Mycoplasma pneumoniae
1 0 1 1 0 0
Streptococcus pneumoniae +
Haemophilus influenzae
2 0 0 0 0
Streptococcus pneumoniae +
Klebsiella pneumoniae
1 1 0 0 0 0
Klebsiella pneumoniae 1 1 0 0 0 0
Haemophilus influenzae 2 2 0 0 0 0
Pseudomonas aeruginosa 2 2* 0 0 0 0
Pseudomonas aeruginosa +
Mycoplasma pneumoniae
2 2* 0 0 0 0
Mycoplasma pneumoniae 4 1* 0 1 0 1
Chlamydophila pneumoniae 4 4* 0 0 0 0
Legionella species 2 1* 1 0 0 0
Unknown 38 21 5 7 5 1
Total 80 47 12 12 6 3
*Antimicrobial agents were used inappropriately
CAP – community acquired pneumonia
cedure was also done on PCR-negative BAL samples. The
inhibitors were detected only in one serum sample in
which PCR remained negative even after spiking with
pneumococcal DNA. Inhibitors were not detected in BAL
samples. Also, after dilution of serum samples with pool-
ing all PCR results in serum samples remained negative.
BAL PCR provided 2 additional diagnoses of S. pneu-
moniae, despite the fact that all patients who underwent
bronchoscopy have received antimicrobial treatment be-
fore procedure. These results are in agreement with pre-
vious reports33,34. Despite 2 additional diagnoses of pneu-
mococcal pneumonia with BAL PCR, BAL culture and
BAL PCR have shown overall a low diagnostic yield with
positive results in only 26.3% (5/19) and 15.8% (3/19) of
patients who underwent bronchoscopy, respectively. The-
se results are not surprising knowing that in our study
BAL was not performed immediately on admission, but
when it was considered clinically indicated due to diag-
nostic or therapeutic difficulties. In studies in which BAL
was performed within 24 hours of admission and before
administration of antimicrobial treatment, yield of BAL
culture and PCR was higher34,35. However, our and simi-
lar studies are showing much better the value of BAL in
patients with CAP in routine clinical situations36.
Although PCR added 1 additional case diagnosed as
M. pneumoniae, majority of cases were diagnosed by se-
rology. In the present study, the results by the 2 ap-
proaches – PCR on samples from respiratory tract and
serology were discordant, which was also the case in pre-
vious studies9. Positive PCR alone without an accompa-
nying serological response can indicate carrier status,
but can also be due to a deficient immune response, a
condition that is common in elderly people. Dorigo-Zet-
sma et al. reported that patients with positive PCR and
negative serology were significantly older than the pa-
tients with positiveM. pneumoniae serology37. Indeed, in
our study the patient with positive PCR for M. pneu-
moniae had negative serology and was 80 years old. The
other way round, negative PCR results in patients with
otherwise serologically confirmed mycoplasma respira-
tory tract disease could be explained by early disappear-
ance of M. pneumoniae due to antimicrobial therapy or
immune response of the host9. Although PCR added only
1 additional case of M. pneumoniae pneumonia, it could
be useful in patients with deficient immune response
that is common in elderly people and immunocompro-
mised patients. All 4 cases of C. pneumoniae were diag-
nosed by serology. The low yield of PCR for M. pneumo-
niae and C. pneumoniae is also reported by other investi-
gators and is suggesting that more reliable rapid tests for
these atypical pathogens are necessary23. Both cases of L.
pneumophila serogroup 1 infection were detected by uri-
nary antigen test. In these 2 patients PCR on sputum
samples was not performed because they could not pro-
duce sputum sample. It is a well-known fact that less
than one-half of patients with Legionella infection can
produce sputum11. In our study PCR on sputum and BAL
samples did not provide an additional diagnosis of Legio-
nella infection. It might be useful to evaluate it on differ-
ent type of clinical samples, as it has recently been
suggested for serum samples38.
In recent studies CRP is again evaluated as a diagnos-
tic tool in patients with CAP. In these studies authors are
occupied with a thought that CRP, as an early marker,
could be useful in predicting the aetiology of CAP and the
initial selection of an adequate empiric antimicrobial
treatment15–19. Some of these studies are actually indi-
cating that serum CRP values could be useful in selecting
empiric antimicrobial treatment. Almirall et al. conclu-
ded that high plasma levels of CRP are more common
when the pathogens are S. pneumoniae and L. pneumo-
phila or when the illness is more severe39. Peters and al.
found positive correlation between S. pneumoniae DNA
load in blood with CRP levels in patients with CAP40. On
the other hand, von Baum et al. found that patients with
Mycoplasma pneumonae pneumonia show a lower in-
flammatory response in terms of CRP values41. In our
study CRP values in patients with pneumonia caused by
S. pneumoniae were not significantly higher than in pa-
tients with other proven aetiological diagnoses. This ob-
servation was also reported by other authors13. In our
study, the highest CRP values were detected in 2 patients
with Legionella infection. Although this number of cases
was too small to be included in statistical analysis, this
data are in agreement with previous studies in which the
mean CRP values in the L. pneumophila group were sig-
nificantly higher than those in the group with other diag-
noses, and the authors raised the question of whether L.
pneumophila triggers more (or different) inflammatory
pathways than other atypical microrganisms39,42. In our
study the lowest CRP values were found in patients with
M. pneumoniae infection. This finding is also in agree-
ment with other similar studies, but our number of cases
was too small to be included in statistical analysis41. Cals
et al. found differences in CRP values between bacterio-
logical and virological causative agents of CAP and also
that CRP assisted in prescribing decisions. As we focused
on bacterial CAP, there is no information about the pres-
ence of virological agents in the respiratory samples of
our patients and their relation to CRP values43.
Although there are studies showing that CRP could be a
useful tool in predicting the aetiology of CAP and the initial
selection of an adequate empirical antimicrobial treatment,
the systematic review by van der Meer et al. is showing
quite opposite. They concluded that testing for CRP is nei-
ther sufficiently sensitive to rule out nor sufficiently spe-
cific to rule in bacterial from viral aetiology of lower respi-
ratory tract infection44. Although we are aware of limita-
tions of our study with regard to small number of patients
with CRP measurements, our results are in agreement
with van der Meer et al. and their statement that the cur-
rent evidence does not support a wide introduction of CRP
as a rapid test to guide antimicrobial treatment44.
Thirty percent of the patients included in the study
received antimicrobial treatment before admission to the
hospital. Although we are aware that previous anti-
microbial treatment changes reliability of microbiologi-
cal methods and CRP measurements, this fact is not di-
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minishing the results of our study. Even more, it allows
us to show the yield of these methods not in a re-
search-oriented setting, but in routine clinical setting
where patients are often treated prior to hospitalization.
Although there was heterogeneity in antimicrobial
regimens, the most widely used antibimicrobial regimen
was beta-lactam monotherapy. In this study, the antimi-
crobial agents that were empirically selected were inap-
propriately administered to 23.8% out of 42 patients with
determined aetiology. In a similar study, Ewig et al. re-
ported that among 19 adult patients with CAP with es-
tablished aetiological agent, 21.0% (4/19) cases would
have been treated with an inappropriate regimen with-
out diagnostic results20. Higher percent of inappropri-
ately treated patients in our study could be explained by
extensive microbiological work-up, including PCR tests,
which helped to establish the aetiological diagnosis in a
larger number of patients than in a previous study.
To our knowledge little is known about consequences
of both appropriate and inappropriate antimicrobial treat-
ment on clinical outcome. There are only 2 existing stud-
ies referring to this problem so far. The first is the one by
Nakayama et al. in which the relation between the em-
pirically selected antimicrobial agent and causative pa-
thogen for 117 cases of CAP was examined. Antimicro-
bials were inappropriately used in 11 (9.4%) cases, but no
patient experienced a relapse or was refractory to the
treatment45. The second study is one by van der Eerden
et al. already mentioned in our paper. In that study there
was no significant difference in length of stay (LOS), 30
day mortality, clinical failure, or resolution of fever be-
tween patients who received pathogen directed treat-
ment and those who received empirical broad spectrum
antimicrobial treatment21.
Interesting similarity between our and study by Na-
kayama et al. is that predominant pathogens in inappro-
priately treated patient were atypical ones: in our study
M. pneumoniae, C. pneumoniae and L. pneumophila
serogoup 1, and in the study by Nakayama et al. viruses
andM. pneumoniae. If in this inappropriately treated pa-
tients outcome is not different, as Nakayama et al. sho-
wed, an ancient question is raised again: what is, if any, a
role of atypical pathogens in CAP and what is their posi-
tion in pathogenesis in relation to S. pneumoniae45?
In our study the most original result displayed is the
percent of patients that receive inappropriate empirical
antimicrobial treatment based on aetiological tests which
also included molecular methods. However, the real value
of molecular methods and their influence on treatment
outcome is yet to be established. Clinically relevant out-
come parameters such as mortality, LOS or readmission
rate should be evaluated to measure cost-benefit of these
methods and their effect on the treatment outcome22,46,47.
Predominant pathogens in inappropriately treated
patients were atypical pathogensM. pneumoniae, C. pneu-
moniae and L. pneumophila serogroup 1. This finding
further emphasize two existing problems: first, a di-
lemma about necessity of empirical antimicrobial cover-
age of atypical pathogens in patients with CAP, and the
second, a need for more reliable rapid tests for the detec-
tion of atypical pathogens25,48–50.
In conclusion, our study indicates that S. pneumoniae
is the most common cause of CAP in adult patients.
Pneumococcal urinary antigen is the most useful test,
but PCR on BAL samples can also provide an additional
diagnosis of pneumococcal pneumonia, even in patients
with previously administered antimicrobial treatment.
As 23.8% of patients were inappropriately treated ac-
cording to aetiological diagnosis, microbiological test in
patients with CAP are still necessary. Particularly PCR
tests for the diagnostics of M. pneumoniae, C. pneumo-
niae and Legionella species need further investigation
and improvement because these causative pathogens are
predominant in inappropriately treated patients. Our re-
sults do not support the use of CRP as a rapid test to
guide antimicrobial treatment.
Until rapid methods are improved, initial decisions
about empirical antimicrobial treatment will still be ba-
sed on the knowledge of predominant microbial patterns
in CAP on particular geographical area. It is therefore
important that teaching hospitals conduct periodic sur-
veys and determine their microbial patterns prevalent in
their hospitalized patients with CAP.
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ZNA^ENJE BRZE ETIOLO[KE DIJAGNOZE U OPTIMIZACIJI ANTIMIKROBNOG LIJE^ENJA
BOLESNIKA S IZVANBOLNI^KOM PNEUMONIJOM UZROKOVANOM BAKTERIJAMA
S A @ E T A K
Kod 80 bolesnika s izvanbolni~kom pneumonijom napravljene su konvencionalne mikrobiolo{ke pretrage i lan~ana
reakcija polimeraze (PCR), te odre|en C-reaktivni protein (CRP) u serumu. Adekvatnost empirijskog antimikrobnog
lije~enja evaluirana je prema detektiranom bakterijskom patogenu. Etiologija je utvr|ena kod 42 (52,5%) bolesnika, a
naj~e{}i patogen bio je Streptococcus pneumoniae. PCR-om na uzorcima bronhoalveolarnih lavata i sputuma utvr|ena
je etiolo{ka dijagnoza kod 2 odnosno 1 bolesnika kod kojih to nije bilo mogu}e s konvencionalnim mikrobiolo{kim meto-
dama. Prosje~ne CRP vrijednosti kod bolesnika sa S. pneumoniae nisu bile statisti~ki zna~ajno ve}e u usporedbi s
onima kod bolesnika s drugom etiologijom pneumonije (166,89 mg/L vs.160,11 mg/L, p=0,457). Kod 23.8% (10/42)
bolesnika s utvr|enom etiologijom empirijsko antimikrobno lije~enje bilo je nedekvatno. PCR metode u dijagnostici
izvanbolni~kih pneumonija zahtijevaju daljnje istra`ivanje. To se osobito odnosi na PCR metode za detekciju atipi~nih
patogena budu}i da oni prevladavaju kod neadekvatno lije~enih bolesnika. Rezultati ovog istra`ivanja ne pokazuju da bi
CRP bio koristan kao brzi test prema kojem bi se usmjeravalo antimikrobno lije~enje kod bolesnika s izvanbolni~kom
pneumonijom.
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